Main public logs

Combined display of all available logs of Azupedia. You can narrow down the view by selecting a log type, the username (case-sensitive), or the affected page (also case-sensitive).

07:22, 3 April 2024 Fire talk contribs created page Template:Metabolism of vitamins, coenzymes, and cofactors/ja (Created page with "{{Navbox | name = Metabolism of vitamins, coenzymes, and cofactors/ja | title = vitamin/ja, 補酵素, 補要素の代謝 | state = {{{state<includeonly>|autocollapse</includeonly>}}} | listclass = hlist | group1 = 脂溶性ビタミン | list1 = {{Navbox|child | group1 = Vitamin A/ja | list1 = * Retinol binding protein/ja | group2 = Vitamin E/ja | list2 = * Alpha-tocopherol transfer...")
07:14, 3 April 2024 Fire talk contribs created page Weight loss drug/ja (Redirected page to 抗肥満薬) Tag: New redirect
07:14, 3 April 2024 Fire talk contribs created page Weight loss drug (Redirected page to Anti-obesity medication) Tag: New redirect
07:12, 3 April 2024 Fire talk contribs created page Translations:GLP1 poly-agonist peptides/7/ja (Created page with "==GLP-1と神経ペプチドYのマルチアゴニスト== {{Anchor|GLP-1 and neuropeptide Y multi-agonists}} 2023年、研究者たちは、GLP-1受容体、神経ペプチドY受容体Y1、神経ペプチドY受容体Y2を活性化する複数のペプチドの発見を公表した。神経ペプチドY受容体は以前から抗肥満薬の標的であったため、この組み合わせはGLP-1受容...")
07:11, 3 April 2024 Fire talk contribs created page Translations:GLP1 poly-agonist peptides/6/ja (Created page with "GLP-1とアミリン受容体作動薬の結合体も前臨床試験でテストされている。")
07:11, 3 April 2024 Fire talk contribs created page Translations:GLP1 poly-agonist peptides/5/ja (Created page with "==共役体== {{Anchor|Conjugates}} エストロゲン、甲状腺ホルモン（T3）、デキサメタゾンなどの他のホルモンをGLP-1やグルカゴンに結合させると、結合したホルモンの活性がGLP-1やグルカゴンを発現している細胞に限定される。")
07:10, 3 April 2024 Fire talk contribs created page Translations:GLP1 poly-agonist peptides/4/ja (Created page with "==GLP-1、GIPおよびグルカゴン受容体トリプルアゴニスト== {{Anchor|GLP-1, GIP, and glucagon receptor triple agonists}} GLP-1/GIPおよびGLP-1/グルカゴンのデュアルアゴニストが発見された後、トリプルアゴニストが相加的または相乗的な代謝効果をもたらすことが期待された。トリプルアゴニストretatrutideの臨床試験では、24週間後に最高用量群で平均-24.2％の...")
07:09, 3 April 2024 Fire talk contribs created page Translations:GLP1 poly-agonist peptides/3/ja (Created page with "==GLP-1およびグルカゴン受容体デュアルアゴニスト== {{Anchor|GLP-1 and glucagon receptor dual agonists}} {{see also/ja|Glucagon receptor agonist/ja}} グルカゴンは一般的にインスリンの作用に対抗するホルモンである。グルカゴンはグリコーゲン分解（グリコーゲンの分解）と糖新生（非炭水化物源からのグルコースの生...")
07:03, 3 April 2024 Fire talk contribs created page Translations:GLP1 poly-agonist peptides/2/ja (Created page with "==GLP-1およびGIP受容体のデュアルアゴニスト== {{Anchor|GLP-1 and GIP receptor dual agonists}} GLP-1とGIP受容体のデュアルアゴニストであるチルゼパチドは、2型糖尿病と肥満症に対して承認されている。高用量で平均20％の体重減少が認められ、GLP-1単独作動薬よりも有効であると思われるが、2023年現在、直接比較試験は行われていない。")
22:48, 2 April 2024 Fire talk contribs created page Translations:GLP1 poly-agonist peptides/8/ja (Created page with "==こちらも参照== *Cagrilintide/semaglutide/ja *Insulin icodec/semaglutide/ja")
22:47, 2 April 2024 Fire talk contribs created page Translations:GLP1 poly-agonist peptides/9/ja (Created page with "Category:GLP-1 receptor agonists Category:Peptide therapeutics")
22:47, 2 April 2024 Fire talk contribs created page Translations:GLP1 poly-agonist peptides/1/ja (Created page with "'''GLP1ポリ拮抗ペプチド'''は、グルカゴン様ペプチド-1（GLP-1）受容体を含む複数のペプチドホルモン受容体を活性化する薬物の一種である。これらの薬物はGLP-1受容体作動薬と同じ適応症、特に肥満症、2型糖尿病、非アルコール性脂肪性肝疾患を対象に開発されている。これらの薬剤...")
22:04, 2 April 2024 Fire talk contribs created page GLP1 poly-agonist peptides/ja (Created page with "GLP1ポリアゴニストペプチド") Tags: Mobile edit Mobile web edit
22:04, 2 April 2024 Fire talk contribs created page Translations:GLP1 poly-agonist peptides/Page display title/ja (Created page with "GLP1ポリアゴニストペプチド")
22:02, 2 April 2024 FuzzyBot talk contribs created page GLP1 poly-agonist peptides/en (Updating to match new version of source page)
22:01, 2 April 2024 FuzzyBot talk contribs created page Translations:GLP1 poly-agonist peptides/9/en (Importing a new version from external source)
22:01, 2 April 2024 FuzzyBot talk contribs created page Translations:GLP1 poly-agonist peptides/8/en (Importing a new version from external source)
22:01, 2 April 2024 FuzzyBot talk contribs created page Translations:GLP1 poly-agonist peptides/7/en (Importing a new version from external source)
22:01, 2 April 2024 FuzzyBot talk contribs created page Translations:GLP1 poly-agonist peptides/6/en (Importing a new version from external source)
22:01, 2 April 2024 FuzzyBot talk contribs created page Translations:GLP1 poly-agonist peptides/5/en (Importing a new version from external source)
22:01, 2 April 2024 FuzzyBot talk contribs created page Translations:GLP1 poly-agonist peptides/4/en (Importing a new version from external source)
22:01, 2 April 2024 FuzzyBot talk contribs created page Translations:GLP1 poly-agonist peptides/3/en (Importing a new version from external source)
22:01, 2 April 2024 FuzzyBot talk contribs created page Translations:GLP1 poly-agonist peptides/2/en (Importing a new version from external source)
22:01, 2 April 2024 FuzzyBot talk contribs created page Translations:GLP1 poly-agonist peptides/1/en (Importing a new version from external source)
22:01, 2 April 2024 FuzzyBot talk contribs created page Translations:GLP1 poly-agonist peptides/Page display title/en (Importing a new version from external source)
22:01, 2 April 2024 Fire talk contribs marked GLP1 poly-agonist peptides for translation
22:01, 2 April 2024 Fire talk contribs limited languages for translatable page GLP1 poly-agonist peptides to Japanese
22:00, 2 April 2024 Fire talk contribs created page GLP1 poly-agonist peptides (Q21692) (wbeditentity-create:2|en: GLP1 poly-agonist peptides)
21:59, 2 April 2024 Fire talk contribs created page GLP1 poly-agonist peptides (Created page with "'''GLP1 poly-agonist peptides''' are a class of drugs that activate multiple peptide hormone receptors including the glucagon-like peptide-1 (GLP-1) receptor. These drugs are developed for the same indications as GLP-1 receptor agonists—especially obesity, type 2 diabetes, and non-alcoholic fatty liver disease. They are expected to provide superior efficacy with fewer adverse effects compared to GLP-1 mono-agonists, which ar...")
21:39, 2 April 2024 Fire talk contribs created page L-Malate + NAD⁺ ⇌ Oxaloacetate + NADH + H⁺ (Q21691) (wbeditentity-create:2|en: L-Malate + NAD⁺ ⇌ Oxaloacetate + NADH + H⁺, chemical reaction)
21:28, 2 April 2024 Fire talk contribs created page hydroxy acid (Q21690) (wbeditentity-create:2|en: hydroxy acid, any organic compound having at least one carboxyl group and at least one hydroxyl group)
21:27, 2 April 2024 Fire talk contribs created page alpha hydroxy acid (Q21689) (wbeditentity-create:2|en: alpha hydroxy acid, any carboxylic acid having hydroxyl group attached to α position in relation to carboxyl group)
21:26, 2 April 2024 Fire talk contribs created page DL-malic acid (Q21688) (wbeditentity-create:2|en: DL-malic acid, group of stereoisomers)
21:23, 2 April 2024 Fire talk contribs created page L-malic acid (Q21687) (wbeditentity-create:2|en: L-malic acid, chemical compound)
21:21, 2 April 2024 Fire talk contribs created page Fumarate + H₂O ⇌ L-Malate (Q21686) (wbeditentity-create:2|en: Fumarate + H₂O ⇌ L-Malate, chemical reaction)
21:19, 2 April 2024 Fire talk contribs created page ubiquinol-10 (Q21685) (wbeditentity-create:2|en: ubiquinol-10, CoQ-10, reduced form)
21:14, 2 April 2024 Fire talk contribs created page fumaric acid (Q21684) (wbeditentity-create:2|en: fumaric acid, chemical compound)
21:03, 2 April 2024 Fire talk contribs created page involuntary movement (Q21683) (wbeditentity-create:2|en: involuntary movement, involuntary contractions of muscle leading to involuntary movements of extremities, neck, trunk, or face)
21:01, 2 April 2024 Fire talk contribs created page Huntington's disease-like syndrome (Q21682) (wbeditentity-create:2|en: Huntington's disease-like syndrome, human disease)
21:00, 2 April 2024 Fire talk contribs created page choreatic disease (Q21681) (wbeditentity-create:2|en: choreatic disease, movement disease characterized by brief, semi-directed, irregular movements that not repetitive or rhythmic, but appear to flow from one muscle to the next)
20:57, 2 April 2024 Fire talk contribs created page HTT (Q21680) (wbeditentity-create:2|en: HTT, protein-coding gene in the species Homo sapiens)
20:56, 2 April 2024 Fire talk contribs created page trinucleotide repeat expansion (Q21679) (wbeditentity-create:2|en: trinucleotide repeat expansion, DNA mutation)
20:55, 2 April 2024 Fire talk contribs created page repeat expansion disorders (Q21678) (wbeditentity-create:2|en: repeat expansion disorders, type of disease)
20:54, 2 April 2024 Fire talk contribs created page trinucleotide repeat disorder (Q21677) (wbeditentity-create:2|en: trinucleotide repeat disorder, a genetic disorders caused by trinucleotide repeat expansion, a kind of mutation where trinucleotide repeats in certain genes or introns exceed the normal, stable threshold, which differs per gene)
20:52, 2 April 2024 Fire talk contribs created page genetic dementia (Q21676) (wbeditentity-create:2|en: genetic dementia, Genetic dementia)
20:51, 2 April 2024 Fire talk contribs created page neurodegenerative disease with dementia (Q21675) (wbeditentity-create:2|en: neurodegenerative disease with dementia, human disease)
20:50, 2 April 2024 Fire talk contribs created page genetic neurodegenerative disease with dementia (Q21674) (wbeditentity-create:2|en: genetic neurodegenerative disease with dementia, instance of neurodegenerative disease with dementia that is caused by a modification of the individual's genome)
20:48, 2 April 2024 Fire talk contribs created page eye degenerative disease (Q21673) (wbeditentity-create:2|en: eye degenerative disease, neurodegenerative disease that involves the eye)
20:46, 2 April 2024 Fire talk contribs created page nervous system heredodegenerative disease (Q21672) (wbeditentity-create:2|en: nervous system heredodegenerative disease, Human disease)
20:45, 2 April 2024 Fire talk contribs created page Huntington disease and related disorders (Q21671) (wbeditentity-create:2|en: Huntington disease and related disorders, human disease)